GLP-1 medications like Ozempic and Wegovy are known for weight loss, but researchers are now asking whether they might also lower the risk of certain cancers. Early studies point to reduced risk across several obesity-related cancers, including liver cancer, likely by easing inflammation, improving insulin levels, and reducing body fat.
A signal for liver health
One finding stands out for liver health: researchers observed that GLP-1s may help lower liver cancer risk in high-risk patients, especially those with type 2 diabetes and fatty liver disease (MASLD). Experts are careful to note the research is still early, and these drugs aren’t approved for cancer prevention, so regular screening and surveillance remain essential.
Why early detection still matters
For people already at higher risk of liver cancer, many of whom feel fine until the disease is advanced, catching it early is what matters most. HelioLiver supports the early detection of hepatocellular carcinoma (HCC) from a simple blood draw, working alongside routine surveillance for at-risk patients.
Source: U.S. News & World Report. Read the full article.